| Q35753007 | A pilot study with a therapeutic vaccine based on hydroxyapatite ceramic particles and self-antigens in cancer patients |
| Q27004178 | Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook |
| Q52671132 | Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells. |
| Q36283034 | Adoptive cell therapy for the treatment of patients with metastatic melanoma |
| Q38146713 | Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. |
| Q24546258 | Adoptive immunotherapy for cancer: building on success |
| Q62746944 | Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors |
| Q49884881 | An Uncoupling of Canonical Phenotypic Markers and Functional Potency of Ex Vivo-Expanded Natural Killer Cells. |
| Q35382043 | Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement |
| Q37655544 | CCR7+ selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo. |
| Q43891437 | CD27 costimulation contributes substantially to the expansion of functional memory CD8(+) T cells after peptide immunization. |
| Q33559655 | CD27 sustains survival of CTLs in virus-infected nonlymphoid tissue in mice by inducing autocrine IL-2 production |
| Q42136462 | CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting. |
| Q39701317 | CD70 and Th17 are involved in human contact sensitivity |
| Q52678805 | CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma. |
| Q48223703 | CD70, a novel target of CAR T-cell therapy for gliomas |
| Q34299986 | CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma |
| Q93133450 | CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors |
| Q37909894 | Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know. |
| Q50554742 | Characterization and comparison of 'standard' and 'young' tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution. |
| Q42280014 | Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patients. |
| Q34331357 | Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: Differing impact on CD8 T cell phenotype and responsiveness to restimulation |
| Q42126236 | Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function |
| Q26773314 | Current status of immunotherapy |
| Q41909731 | Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21 |
| Q36442539 | Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma |
| Q24596055 | Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy |
| Q38266264 | Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes |
| Q42205543 | Epitope-specific regulation of memory programming by differential duration of antigen presentation to influenza-specific CD8(+) T cells. |
| Q34141754 | Ex vivo expansion of human CD8+ T cells using autologous CD4+ T cell help |
| Q92650477 | Examining Peripheral and Tumor Cellular Immunome in Patients With Cancer |
| Q38525044 | Exploiting cytokines in adoptive T-cell therapy of cancer |
| Q37576033 | Exploiting the curative potential of adoptive T-cell therapy for cancer |
| Q34111789 | Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma |
| Q21328679 | Focus on adoptive T cell transfer trials in melanoma |
| Q40704505 | Host factors associated with serologic inflammatory markers assessed using multiplex assays |
| Q34391263 | Human cell-based artificial antigen-presenting cells for cancer immunotherapy |
| Q34557953 | Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. |
| Q36327148 | IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells |
| Q36677310 | IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy |
| Q36767295 | IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells. |
| Q34743514 | Immunotherapy for ovarian cancer: what's next? |
| Q35861249 | Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer |
| Q36803857 | Impacts of HIV infection on Vgamma2Vdelta2 T cell phenotype and function: a mechanism for reduced tumor immunity in AIDS |
| Q28068378 | Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination |
| Q34073529 | In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB) |
| Q37708023 | Induction/engineering, detection, selection, and expansion of clinical-grade human antigen-specific CD8 cytotoxic T cell clones for adoptive immunotherapy |
| Q33688931 | Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma. |
| Q39904721 | Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells |
| Q53246103 | International meeting "Immunotherapy of cancer: challenges and needs". |
| Q34982519 | Irradiation enhances human T-cell function by upregulating CD70 expression on antigen-presenting cells in vitro |
| Q27026665 | Lineage relationship of effector and memory T cells |
| Q39418546 | Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy |
| Q34823783 | Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy |
| Q40146544 | PD-1+ Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer |
| Q36835181 | PILAR is a novel modulator of human T-cell expansion |
| Q34300932 | Paths to stemness: building the ultimate antitumour T cell. |
| Q36351988 | Phenotypic characterization and anticancer capacity of CD8+ cytokine-induced killer cells after antigen-induced expansion |
| Q84600405 | Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein |
| Q42214248 | Pro-survival signaling via CD27 costimulation drives effective CAR T-cell therapy |
| Q49574295 | Protective role of the co-stimulator CD27 receptor and regulatory T cells in early atherogenesis |
| Q41832380 | Receptor desensitization and blockade of the suppressive effects of prostaglandin E2 and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes |
| Q37779170 | Role of CD27/CD70 pathway of activation in immunity and tolerance |
| Q35860034 | Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment |
| Q33855420 | Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity |
| Q27002575 | Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? |
| Q24598792 | Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients |
| Q30252919 | Stimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancer |
| Q34923799 | T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies |
| Q39070577 | T memory stem cells in health and disease. |
| Q34090686 | TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma |
| Q38543791 | TH17 is involved in the remarkable regression of metastatic malignant melanoma to topical diphencyprone |
| Q33961011 | The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity |
| Q34080914 | Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired |
| Q38726535 | Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM. |
| Q38636573 | Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. |
| Q37561102 | Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy |
| Q36960476 | Use of high throughput qPCR screening to rapidly clone low frequency tumour specific T-cells from peripheral blood for adoptive immunotherapy |